Table 3.

Results of the adjusted base-case and subgroup analyses

	Levetiracetam	Valproate	Incremental
Base-case all participants (n=520)
Total costs (£)	4350 (4136 to 5623)	4246 (3979 to 5090)	104 (−587 to 1234)
QALYs	1·603 (1·500 to 1·631)	1·637 (1·565 to 1·673)	−0·035 (−0·103 to 0·077)
Net health benefit at £20 000 per QALY (QALYs)	1·385 (1·236 to 1·410)	1·425 (1·323 to 1·464)	−0·040 (−0·175 to 0·037)
Children aged <16 years (n=312)
Total costs (£)	4336 (4017 to 5516)	4360 (4046 to 5149)	−24 (−752 to 1065)
QALYs	1·624 (1·506 to 1·646)	1·626 (1·554 to 1·667)	−0·002 (−0·123 to 0·054)
Net health benefit at £20 000 per QALY	1·407 (1·254 to 1·430)	1·408 (1·307 to 1·455)	−0·002 (−0·136 to 0·062)
Adults and adolescents aged ≥16 years (n=208)
Total costs (£)	4316 (3842 to 5898)	3957 (3525 to 5161)	359 (−644 to 1640)
QALYs	1·576 (1·474 to 1·636)	1·654 (1·563 to 1·693)	−0·078 (−0·175 to 0·015)
Net health benefit at £20 000 per QALY	1·407 (1·200 to 1·425)	1·456 (1·330 to 1·497)	−0·090 (−0·208 to 0·018)

Data are mean (95% CI). QALY=quality-adjusted life-years.